Global Cervical Intraepithelial Neoplasia Drugs Market
시장 규모 (USD 10억)
연평균 성장률 : %
예측 기간 |
2022 –2029 |
시장 규모(기준 연도) |
USD 525.75 Million |
시장 규모(예측 연도) |
USD 857.13 Million |
연평균 성장률 |
|
주요 시장 플레이어 |
>세계 자궁경부 상피내 종양 약물 시장, 질병 유형별(자궁경부 상피내 종양 1, 자궁경부 상피내 종양 2, 자궁경부 상피내 종양 3), 치료(수술, 약물, 기타), 투여 형태(용액, 분말, 주사, 크림, 기타), 투여 경로( 정맥 주사 , 국소, 기타), 적응증(악성 전 병변, 초기 침습 단계, 진행된 침습 단계), 최종 사용자(병원, 전문 병원, 홈 케어, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국, 기타) - 2029년까지의 산업 동향 및 예측
시장 분석 및 규모
미국 암 협회에 따르면, 2020년에 미국에서 약 13,800건의 침습성 자궁 경부암 신규 환자가 진단될 것으로 예상되며, 4,290명의 여성이 이 질병으로 사망할 것으로 예상됩니다. 자궁 경부 상피내 종양은 종종 무증상이며 표준 자궁 경부 세포 검사로 발견됩니다. 자궁 경부 상피내 종양은 30세 미만의 여성에게 더 흔하지만 모든 연령대에서 발생할 수 있습니다. 이는 성병인 인유두종 바이러스(HPV) 감염과 밀접한 관련이 있습니다. 아바스틴, 블레모신, 베바시주맙, 블레녹산 등은 자궁 경부 상피내 종양을 치료하는 데 사용되는 다양한 유형의 약물이며 소매 약국, 병원, 약국 등을 포함한 다양한 채널을 통해 유통됩니다.
Data Bridge Market Research는 자궁 경부 상피내 종양 약물 시장이 2021년에 5억 2,575만 달러 규모였으며 2029년까지 8억 5,713만 달러에 도달할 것으로 예상되며 2022년부터 2029년까지의 예측 기간 동안 6.30%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.
보고 범위 및 시장 세분화
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
양적 단위 |
매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시 |
다루는 세그먼트 |
질병 유형(자궁경부 상피내 종양 1형, 자궁경부 상피내 종양 2형, 자궁경부 상피내 종양 3형), 치료(수술, 약물, 기타), 투여 형태(용액, 분말, 주사, 크림, 기타), 투여 경로(정맥 주사, 국소, 기타), 적응증(악성 전 병변, 초기 침습 단계, 진행된 침습 단계), 최종 사용자(병원, 전문 병원, 홈 케어, 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국, 기타) |
적용 국가 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), Biocon (India), Amgen Inc. (US), Eli Lilly and Company (US), Allergan (Ireland), Hetero (India), Abbott (US), QIAGEN (Netherlands), Danaher (US) |
Market Opportunities |
|
Market Definition
Cervical intraepithelial neoplasia (CIN) is a disorder in which the cervix grows aberrant cells. Certain kinds of the human papillomavirus (HPV), as well as other environmental variables, can cause it, and it can sometimes lead to cervical cancer precursors. Cervical cancer is uncommon, although cervical intraepithelial neoplasia is not. The bottom section of the uterus that goes into the vaginal canal is known as the cervix. During childbirth, the cervix dilates to allow the foetus to pass through. The aberrant cells in cervical intraepithelial neoplasia aren't malignant. It can, however, grow into precancers or cancer if not monitored or treated in certain circumstances that require therapy. This condition is also termed as cervical dysplasia.
Cervical Intraepithelial Neoplasia Drugs Market Dynamics
Drivers
- Rise in the prevalence of human papillomavirus (HPV) infection
The surging prevalence of human papillomavirus (HPV) infection is a major factor driving the cervical intraepithelial neoplasia drugs market's growth rate. Cervical HPV infection is a sexually transmitted disease that increases the risk of cervical intraepithelial neoplasia. Only a small fraction of women infected with the virus may develop severe CIN or invasive cervical cancer. The HPV genotype that causes the infection is the most important determinant in determining whether the infection will develop to CIN. Despite the fact that there are around 100 subtypes of HPV, only a tiny subset has been linked to cervical dysplasia and cancer. HPV subtypes are classified as cancer-causing or non-cancerous. Another important determinant in the development of CIN and, eventually, cancer is the virus's persistence in tissues. HPV infection can affect sexually active women of any age, but it is more common in adolescent and younger women. Women between the ages of 20 and 24 had the highest occurrence.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cervical intraepithelial neoplasia drugs market is the rising healthcare expenditure which helps in improving its infrastructure.
- Surging frequency of human immunodeficiency virus (HIV) in women
The cervical intraepithelial neoplasia drugs market is growing due to the rising frequency of human immunodeficiency virus (HIV) in women. Cervical cancer is more common among HIV-positive women than in the general population. Nearly 18 million women in the world have tested positive for HIV. HIV impairs the immune system, increasing the risk of cervical cancer. Because the count of the protein CD4 decreases in HIV-positive women, they are more likely to be diagnosed with cervical intraepithelial neoplasia. A person with HIV is at the highest risk of getting cervical cancer, as per the study done by the National Cancer Institute.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cervical intraepithelial neoplasia drugs market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of cervical intraepithelial neoplasia drugs market. Along with this, the rising prevalence of cervical cancer and the dearth of awareness regarding diagnostic tests for prevention of invasive cancer will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by the rise in the number of research and development activities. This will provide beneficial opportunities for the cervical intraepithelial neoplasia drugs market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cervical intraepithelial neoplasia drugs market growth during the forecast period.
Restraints/Challenges
On the other hand, the expiration of patented drugs and the introduction of generic version of drugs will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and the high cost associated with drugs will challenge the cervical intraepithelial neoplasia drugs market. Additionally, side effects linked with cervical intraepithelial neoplasia drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This cervical intraepithelial neoplasia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cervical intraepithelial neoplasia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cervical intraepithelial neoplasia affects between 250,000 and 1 million cisgender women in the United States each year. The illness is most common in women of childbearing age, especially those between 25 and 35.
Cervical intraepithelial neoplasia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cervical Intraepithelial Neoplasia Drugs Market
The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had an impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact. The pandemic's lockdown has put a financial strain on the private healthcare industry in a number of countries. Outpatient visits, manpower, equipment, consumables, and other resources were reduced. Furthermore, the coronavirus pandemic had a significant influence on medicine development, production, supply, and the businesses of different healthcare corporations around the world. The outbreak has resulted in the shutdown of industrial establishments, with the exception of those that manufacture critical commodities, and disruptions in product supply chains. As a result, the COVID-19 outbreak had impacted the economy in three ways: directly influencing production and demand, causing distribution channel disruptions, and having a financial impact on firms and financial markets. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. Hence, the market is projected to stabilize in the future.
Recent Development
- In September 2021, the US Food and Drug Administration (FDA) had announced the approval of tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. It is a tissue factor-directed antibody as well as microtubule inhibitor conjugate used for the treatment of adults patients with recurrent or metastatic cervical cancer. 2 mg/kg (up to a maximum of 200 mg for patients ≥100 kg) is the recommended dose which is given as an intravenous infusion over 30 minutes every 3 weeks.
Global Cervical Intraepithelial Neoplasia Drugs Market Scope
The cervical intraepithelial neoplasia drugs market is segmented on the basis of disease type, treatment, indication, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Cervical Intraepithelial Neoplasia 1
- Cervical Intraepithelial Neoplasia 2
- Cervical Intraepithelial Neoplasia 3
Treatment
- Surgery
- Hysterectomy
- Cone biopsy
- Loop electrosurgical excision procedure (LEEP)
- Laser therapy
- Cryosurgery
- Medication
- Avastin
- Bevacizumb
- Blemocin
- Blenoxane
- Others
- Others
Indication
- Pre-malignant Lesions
- Early Invasive Stage
- Advanced Invasive Stage
Dosage Form
- Solution
- Powder
- Injection
- Cream
- Others
Route of Administration
- Intravenous
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Cervical Intraepithelial Neoplasia Drugs Market Regional Analysis/Insights
The cervical intraepithelial neoplasia drugs market is analysed and market size insights and trends are provided by country, disease type, treatment, indication, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the cervical intraepithelial neoplasia drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the cervical intraepithelial neoplasia drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, surging awareness and government-embedded reimbursement policies will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of human papillomavirus (HPV) infection in this region. Also, development of healthcare infrastructure will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cervical Intraepithelial Neoplasia Drugs Market Share Analysis
The cervical intraepithelial neoplasia drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cervical intraepithelial neoplasia drugs market.
자궁 경부 상피내 종양 약물 시장에서 활동하는 주요 업체는 다음과 같습니다.
- 파이저 주식회사(미국)
- GlaxoSmithKline plc (영국)
- 노바티스 AG(스위스)
- 마일런 NV(미국)
- Teva Pharmaceutical Industries Ltd. (이스라엘)
- 사노피(프랑스)
- 베링거 인겔하임 인터내셔널 GmbH. (독일)
- 아스트라제네카(영국)
- 존슨앤존슨 프라이빗 리미티드(미국)
- 머크앤코(미국)
- F. 호프만-라 로슈 유한회사(스위스)
- 브리스톨-마이어스 스퀴브 회사(미국)
- Biocon(인도)
- 암젠 주식회사(미국)
- 엘리 릴리 앤드 컴퍼니(미국)
- 알러간(아일랜드)
- 헤테로(인도)
- 애벗(미국)
- QIAGEN(네덜란드)
- 다나허(미국)
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.